Zacks Research Issues Pessimistic Outlook for APLS Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at Zacks Research lowered their Q2 2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued on Tuesday, May 27th. Zacks Research analyst R. Department now expects that the company will post earnings per share of ($0.46) for the quarter, down from their previous estimate of ($0.34). The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Zacks Research also issued estimates for Apellis Pharmaceuticals’ Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.06) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.67) EPS, Q1 2027 earnings at ($0.30) EPS and FY2027 earnings at ($0.42) EPS.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Wednesday, May 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.38). The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. Apellis Pharmaceuticals’s revenue was down 3.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.54) EPS.

Several other analysts also recently issued reports on the company. Scotiabank cut their price target on Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a report on Thursday, May 8th. Mizuho cut their price target on Apellis Pharmaceuticals from $30.00 to $20.00 and set a “neutral” rating on the stock in a report on Wednesday, May 14th. Citigroup cut their target price on Apellis Pharmaceuticals from $49.00 to $41.00 and set a “buy” rating on the stock in a research note on Thursday, May 22nd. Robert W. Baird cut their target price on Apellis Pharmaceuticals from $55.00 to $47.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th. Finally, Royal Bank of Canada cut their target price on Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating on the stock in a research note on Thursday, May 8th. Nine research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Apellis Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $39.89.

Apellis Pharmaceuticals Trading Down 2.9%

Shares of NASDAQ APLS opened at $16.91 on Friday. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -8.33 and a beta of 0.73. Apellis Pharmaceuticals has a 12-month low of $16.10 and a 12-month high of $43.76. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock’s 50 day simple moving average is $18.91 and its 200 day simple moving average is $25.92.

Insider Buying and Selling

In related news, General Counsel David O. Watson sold 5,569 shares of Apellis Pharmaceuticals stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the transaction, the general counsel now directly owns 138,730 shares in the company, valued at $3,482,123. The trade was a 3.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 6.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Avoro Capital Advisors LLC grew its holdings in shares of Apellis Pharmaceuticals by 10.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company’s stock valued at $390,011,000 after buying an additional 1,111,111 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Apellis Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 10,130,356 shares of the company’s stock valued at $221,551,000 after buying an additional 84,331 shares in the last quarter. AQR Capital Management LLC boosted its position in Apellis Pharmaceuticals by 119.6% during the first quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company’s stock valued at $89,173,000 after purchasing an additional 2,220,977 shares during the last quarter. Jennison Associates LLC boosted its position in Apellis Pharmaceuticals by 51.6% during the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after purchasing an additional 939,289 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Apellis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company’s stock valued at $58,699,000 after purchasing an additional 28,426 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).